Related Experiment Video
Updated: Jan 27, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
Published on: March 17, 2023
Subcutaneous Tocilizumab for Thyroid Eye Disease: Simplified Dosing and Delivery
Thomas Copperman1, Oluwatobi O Idowu, Robert C Kersten
1Department of Ophthalmology, University of California, San Francisco, San Francisco, California, U.S.A.
Subcutaneous tocilizumab offers an effective treatment for moderate to severe thyroid eye disease. Home administration over a biweekly course improved clinical activity and proptosis in two patients.
Area of Science:
- Ophthalmology
- Endocrinology
- Immunology
Background:
- Thyroid eye disease (TED) is a complex autoimmune condition affecting the eye socket.
- Intravenous tocilizumab has shown efficacy in treating moderate to severe active TED.
- Optimizing administration routes for tocilizumab in TED management is an area of interest.
Related Concept Videos
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Dose Size and Dosing Frequency: Determination Methods

